Optas LLC Purchases 68 Shares of Stryker Co. (NYSE:SYK)

Optas LLC raised its position in shares of Stryker Co. (NYSE:SYK) by 9.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 815 shares of the medical technology company’s stock after purchasing an additional 68 shares during the quarter. Optas LLC’s holdings in Stryker were worth $293,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Chicago Capital LLC boosted its holdings in shares of Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after buying an additional 5,841 shares during the last quarter. Abner Herrman & Brock LLC boosted its stake in shares of Stryker by 1.5% during the 4th quarter. Abner Herrman & Brock LLC now owns 31,880 shares of the medical technology company’s stock worth $11,478,000 after acquiring an additional 475 shares during the last quarter. FSM Wealth Advisors LLC grew its position in shares of Stryker by 2.4% during the 4th quarter. FSM Wealth Advisors LLC now owns 1,933 shares of the medical technology company’s stock valued at $738,000 after acquiring an additional 45 shares during the period. Baskin Financial Services Inc. raised its holdings in Stryker by 0.7% in the 4th quarter. Baskin Financial Services Inc. now owns 112,198 shares of the medical technology company’s stock worth $40,397,000 after purchasing an additional 816 shares during the period. Finally, CENTRAL TRUST Co lifted its position in Stryker by 0.5% during the fourth quarter. CENTRAL TRUST Co now owns 14,823 shares of the medical technology company’s stock valued at $5,337,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Evercore ISI raised their price objective on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Barclays raised their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Truist Financial upped their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Citigroup lifted their target price on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group increased their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Stryker Stock Up 0.4 %

Shares of NYSE:SYK opened at $392.55 on Wednesday. The company has a market cap of $149.65 billion, a price-to-earnings ratio of 50.59, a PEG ratio of 2.78 and a beta of 0.96. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $376.81 and a 200 day moving average price of $363.64.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. As a group, equities research analysts predict that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.86%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend was Tuesday, December 31st. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.